David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Oct

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

HER2-Negative Advanced Gastric Cancers First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit

Insurance and Cost Barriers to Oral Therapies for Blood Cancers

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer